Literature DB >> 2052620

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

G Gaidano1, P Ballerini, J Z Gong, G Inghirami, A Neri, E W Newcomb, I T Magrath, D M Knowles, R Dalla-Favera.   

Abstract

We have investigated the frequency of p53 mutations in B- and T-cell human lymphoid malignancies, including acute lymphoblastic leukemia, the major subtypes of non-Hodgkin lymphoma, and chronic lymphocytic leukemia. p53 exons 5-9 were studied by using genomic DNA from 197 primary tumors and 27 cell lines by single-strand conformation polymorphism analysis and by direct sequencing of PCR-amplified fragments. Mutations were found associated with (i) Burkitt lymphoma (9/27 biopsies; 17/27 cell lines) and its leukemic counterpart L3-type B-cell acute lymphoblastic leukemia (5/9), both of which also carry activated c-myc oncogenes, and (ii) B-cell chronic lymphocytic leukemia (6/40) and, in particular, its stage of progression known as Richter's transformation (3/7). Mutations were not found at any significant frequency in other types of non-Hodgkin lymphoma or acute lymphoblastic leukemia. In many cases, only the mutated allele was detectable, implying loss of the normal allele. These results suggest that (i) significant differences in the frequency of p53 mutations are present among subtypes of neoplasms derived from the same tissue; (ii) p53 may play a role in tumor progression in B-cell chronic lymphocytic leukemia; (iii) the presence of both p53 loss/inactivation and c-myc oncogene activation may be important in the pathogenesis of Burkitt lymphoma and its leukemic form L3-type B-cell acute lymphoblastic leukemia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052620      PMCID: PMC51883          DOI: 10.1073/pnas.88.12.5413

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

Review 2.  Molecular genetic approaches in the diagnosis and classification of lymphoid malignancies.

Authors:  J J Krolewski; R Dalla-Favera
Journal:  Hematol Pathol       Date:  1989

3.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

4.  A variation in the structure of the protein-coding region of the human p53 gene.

Authors:  V L Buchman; P M Chumakov; N N Ninkina; O P Samarina; G P Georgiev
Journal:  Gene       Date:  1988-10-30       Impact factor: 3.688

5.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

6.  Analysis of RAS oncogene mutations in human lymphoid malignancies.

Authors:  A Neri; D M Knowles; A Greco; F McCormick; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

8.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

9.  Expression of p53 in human leukemia and lymphoma.

Authors:  M Prokocimer; M Shaklai; H B Bassat; D Wolf; N Goldfinger; V Rotter
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  152 in total

Review 1.  Gene expression profiling of lymphomas.

Authors:  U Hegde; W H Wilson
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

2.  Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas.

Authors:  M Sol Mateo; M Mollejo; R Villuendas; P Algara; M Sánchez-Beato; B Martinez-Delgado; P Martínez; M A Piris
Journal:  Mol Pathol       Date:  1998-10

3.  Selective genetic analysis of p53 immunostain positive cells.

Authors:  M Phelps; B S Wilkins; D B Jones
Journal:  Mol Pathol       Date:  2000-06

4.  Clonal evolution of B cells in transformation from low- to high-grade lymphoma.

Authors:  A Matolcsy; E J Schattner; D M Knowles; P Casali
Journal:  Eur J Immunol       Date:  1999-04       Impact factor: 5.532

5.  Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.

Authors:  I K Ruf; P W Rhyne; C Yang; J L Cleveland; J T Sample
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

7.  PCR detection of a neutral CGA/CGG dimorphism in exon 6 of the human p53 gene.

Authors:  K Bhatia; M I Gutiérrez; K Huppi; I T Magrath
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

8.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

9.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.

Authors:  Monica Messina; Ilaria Del Giudice; Hossein Khiabanian; Davide Rossi; Sabina Chiaretti; Silvia Rasi; Valeria Spina; Antony B Holmes; Marilisa Marinelli; Giulia Fabbri; Alfonso Piciocchi; Francesca R Mauro; Anna Guarini; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Robin Foà
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

10.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.